Dwight Gorham: Tommy, can you answer that one?
Tommy Kenny: I mean they will probably – if they issue anything, they will probably only issue it upon receiving the product because they don’t want to create expectation from their patient or customer before the product is actually available.
Unidentified Analyst: Okay. And if the share price continues to wane down where it is now, do you all have any indication or idea if atai would purchase shares on the open market?
Andre Godin: I can answer that. I think that atai has warrants and available. I doubt that their business model allow them to purchase shares on the open market, but they could bring in money by exercising either more convert that they have or warrants that they have. But they are there to support us. Obviously, the – as you probably know, they have supported us through a term loan as well. But one of the objectives of the company, with all the execution that has taken place the last six months and that continues towards 2024 will be out there road showing. I just came back from a road show in South Florida and that will continue. So unfortunately, small cap has been hit quite a bit in the market, especially life science. But as long as we execute on our business plan and that we get closer and closer to being commercial, I think that the stock price will reflect that at some point in 2024. I’m not worried.
Unidentified Analyst: Okay. Thank you.
Operator: Thank you. And the next question is going to be from David Nguyen, who’s a Private Investor. David, your line is live.
David Nguyen: Thank you. Gentlemen, thank you for the update and your progress. It’s good to see that real progress is being made. But being that said, we have a couple of products that have already been approved in various countries, including the United States. And I think it’s fair to say that there’s been some hiccups in commercialization. Moving forward with Montelukast being probably the jewel of the company, are there any basic criteria for choosing a commercialization partner? Because God willing, that drug gets approved for AZ and maybe PD. What is the criteria for choosing a commercialization partner? Because obviously with prior approved products, we haven’t seen real revenues from that.
Dwight Gorham: That’s a great question. Thank you very much. The – from a criteria perspective, I think if the Monte [ph] hits, there’ll be much more mature companies, much larger scale companies involved in the bidding for the product. And certainly some of the criteria will be scale. Others will be international reach, and others will be specifically focused to reach into the U.S. and to Europe. So for me, it’s mostly going to be scale and size to the enterprise to make this happen. With some of the other products, we were – we had partners and we didn’t quite understand some of the logistics associated with holding their hands to get to market. And that’s been cleared up and I think we’ve fixed that. And if Monte hits, I don’t think there’s a lack of partners. It’ll be significantly into their choosing and scale and the credibility organization will be key attributes we’d look at.
David Nguyen: I appreciate that answer there. I just hope that the – I know you’ve only been here for a short time, but I just hope the company can learn from the missteps with already approved drugs and maybe make the next few drugs that we get approved huge successes. So thank you for your time.
Dwight Gorham: Yes. Thank you as well for the question.
Operator: Thank you. And we would now like to hand the call back to Mr. Gorham for closing remarks.
Dwight Gorham: Yes. Thank you very much. Well, this concludes our third quarter 2023 investor call. I’d once again like to thank the entire IntelGenx team for its hard work and dedication, our Board of Directors for the continued support of the management team, and finally, our investors for the continuing belief in and supporting us. The quality of the questions was excellent today. Thank you very much. Thank you, and goodbye.
Operator: Thank you. This does conclude today’s conference call. You may disconnect your phone lines at this time and have a wonderful day. Thank you for your participation.
